 |
|
|
| |
Resistance monitoring data from treatment-naïve chronic HBV infected patients treated for 28
days with a new Class A core protein allosteric modulator RO7049389 monotherapy
|
| |
| |
EASL 2020 Aug 27-29 virtual
Reported by Jules Levin
Xue Zhou1, Remi Kazma2, Dominik Matthias Meinel2, Yuan Zhou1, Junjun Cheng1, Man-Fung Yuen3, Edward Gane4, Christian Schwabe4, Tawesak Tanwandee5, Julian Zhou6, Qingyan Bo1
1 Roche Innovation Centre Shanghai, Shanghai, China; 2 Roche Innovation Centre Basel, Basel, Switzerland; 3 The University of Hong Kong, Hong Kong, China; 4 Auckland Clinical Studies, Auckland, New Zealand; 5 Mahidol University, Bangkok, Thailand; 6 Roche Products Limited, Shanghai, China
|
| |
|
|
|
|
|
